We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Avacta
Diagnostics build-out continues with Coris acquisitionRedx Pharma
Two key Phase II results on track for next 12 monthsRedx Pharma
ROCK solid start in cancer-associated fibrosisAvacta
Building on Therapeutic and Diagnostic foundationsAvacta
FY22 results point to progress across Tx and DxANGLE
Recent deals provide evidence of assay tractionArecor Therapeutics
Continued delivery with key AT278 data due in Q423Futura Medical
Gearing up for further launches in 2023Redx Pharma
Fundamentals intact with catalysts on the horizonHUTCHMED
Significant 2022 achievements catalyse a promising 2023